An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

Alberto Gabizón(Shaare Zedek Medical Center), Rut Isacson(Shaare Zedek Medical Center), Ora Rosengarten(Shaare Zedek Medical Center), Dina Tzemach(Shaare Zedek Medical Center), Hilary Shmeeda(Shaare Zedek Medical Center), Rama Sapir(Shaare Zedek Medical Center)
Cancer Chemotherapy and Pharmacology
June 4, 2007
10.1007/s00280-007-0525-5
Cited by 111

Abstract

Related Papers

Pharmacokinetics of Pegylated Liposomal Doxorubicin
Alberto Gabizón, Hilary Shmeeda, Yechezkel Barenholz|Clinical Pharmacokinetics|2003|1.6k
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Alberto Gabizón, Raphael Catane, Beatrice Uziely et al.|PubMed|1994|1.4k
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Alan N. Gordon, John Fleagle, David Guthrie et al.|Journal of Clinical Oncology|2001|1.2k
Sterically stabilized liposomes
Martin C. Woodle, Danilo D. Lasic|Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes|1992|949
Pharmacokinetics of stealth versus conventional liposomes: effect of dose
Theresa M. Allen, Cecilie Cetti Hansen|Biochimica et Biophysica Acta (BBA) - Biomembranes|1991|573